PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Acta Materia Medica · 2022
DOI: 10.15212/amm-2022-0010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Materia Medica, 2022. Verfasst von Xin Han und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute of the 2nd Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310029, Chi…. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Mouse double minute 2 (MDM2) is an oncogenic E3 ligase that effectively degrades the tumor suppressor p53. In the past two decades, many MDM2 inhibitors that disrupt MDM2-p53 binding have been discovered and developed. Given that MDM2 and p53 form an auto-regulatory loop, in which p53 undergoes targeted degradation as a substrate of MDM2, and p53 targets MDM2 for transcriptional upregulation, these MDM2 inhibitors have limited efficacy. After rapid in vivo clearance of the MDM2 inhibitors, p53 is degraded by accumulated MDM2. Fortunately, proteolysis targeting chimeras (PROTACs), a novel therapeutic strategy, overcome the limitations of MDM2 inhibitors. Several MDM2 inhibitors developed in the past two decades have been used in PROTAC technology in two applications: 1) binding and targeting endogenous MDM2 for PROTAC-based degradation and 2) binding endogenous MDM2 as a PROTAC E3 ligand for PROTAC-based degradation of other oncogenic proteins. In this review, we summarize current progress in the discovery and development of MDM2-based PROTAC drugs, and discuss future perspectives and challenges in their application as effective treatments for human cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Institute of the 2nd Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310029, China.
- Cancer Center, Zhejiang University, Hangzhou 310014, China.
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
- Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.
Förderung
- NCI NIH HHS
Zitieren
APA
Han, X., Wei, W., & Sun, Y. (2022). PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective. Acta Materia Medica. https://doi.org/10.15212/amm-2022-0010
Vancouver
Han X, Wei W, Sun Y. PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective. Acta Materia Medica. 2022. doi:10.15212/amm-2022-0010
BibTeX
@article{Han2022,
author = {Han, Xin and Wei, Wenyi and Sun, Yi},
title = {PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective},
journal = {Acta Materia Medica},
year = {2022},
doi = {10.15212/amm-2022-0010}
}
EUVIMED